The U.S. Food and Drug Administration has announced a nationwide recall of nasal spray, which officials report has been found ...

Milestone Pharmaceuticals announced the FDA approval of prescription etripamil nasal spray for the treatment of acute ...

Milestone Pharmaceuticals Inc.’s CARDAMYST nasal spray wins FDA approval for PSVT, but faces tough competition and market ...

ReBoost Nasal Spray was recalled after it was "found to contain yeast/mold and microbial contamination," the FDA states, adding, "There is a reasonable probability that adverse health consequences, ...

The FDA approved etripamil (Cardamyst) nasal spray for at-home treatment of paroxysmal supraventricular tachycardia (PSVT), ...

Respiratory viruses that have diverse strains and mutate rapidly, such as influenza and COVID-19, are difficult to block ...

The self-administered treatment rapidly converts patients into sinus rhythm and may reduce trips to the hospital.

The FDA had previously turned back the heart rhythm nasal spray twice, once in late 2023 with a refusal to file letter and ...

The FDA approved Milestone Pharmaceuticals' Cardamyst nasal spray for acute episodes of PSVT in adults. First treatment for ...

Clearing clinical and regulatory hurdles in the development of a fast-acting nasal spray for a heart condition has given ...

(NEXSTAR) — A New Mexico company has voluntarily recalled one lot of nasal spray sold nationwide after it was found to ...

The voluntary recall of ReBoost Nasal Spray was issued Wednesday by MediNatura New Mexico, according to an announcement from ...